IMVT
Immunovant Inc
NASDAQ: IMVT · HEALTHCARE · BIOTECHNOLOGY
$30.53
+7.54% today
Updated 2026-11-06
Market cap
$6.12B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.82
Dividend yield
—
52W range
$21 – $45
Volume
1.5M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.3
Quality
B3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
1.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$48.88
+60.10%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy11 Buy4 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 2/9 — weak financial health
- Altman Z 1.64 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-124.41M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $7.09M |
| Net income | $-210.96M | $-259.34M | $-413.84M | $-505.61M | $-153.22M |
| EPS | — | — | — | — | $-2.82 |
| Free cash flow | $-188.39M | $-214.59M | $-376.63M | $-407.32M | $-124.41M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-09-23 | VAN, TUYL CHRISTOPHER | Sale | 2,846 | $36.36 |
| 2026-08-28 | PANDE, ATUL | Sale | 1,500 | — |
| 2026-08-28 | PANDE, ATUL | Buy | 1,500 | $8.43 |
Peer comparison
Smart narrative
Immunovant Inc trades at $30.53. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 1.64, it sits in the distress.
Frequently asked questions
What is Immunovant Inc's stock price?
Immunovant Inc (IMVT) trades at $30.53.
Is Immunovant Inc overvalued?
Immunovant Inc carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Immunovant Inc (IMVT)?
The 12-month analyst consensus target is $48.88, about 60.1% above the current $30.53. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Immunovant Inc's Altman Z-Score is 1.64, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-59.30%
Beta0.84
50D MA$34.86
200D MA$32.03
Shares out0.21B
Float0.09B
Short ratio—
Avg volume1.5M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—